Skip to main content
Equibles
GTBP logo

GTBP · GT Biopharma, Inc. · Metrics

Track GTBP — free

Use GTBP with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research GTBP.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$3.72 -0.12 (-3.13%) At close · Nov 13 Q2 2021 earnings call transcript
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year of the date that the financial statements are issued. In addition, the Company's independent registered public accounting firm, in its report on the Company's December 31, 2025 financial statements, raised substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$6.71M
Shares
1.80M
Volume · Nov 13 66.92K Avg daily vol (48 sessions) 89.87K

GTBP metrics

49 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.72
Market cap
$6.71M

Price action

23 metrics
Price change (1W)
-15.8%
Price change (30D)
-49.5%
Price change (3M)
—
Price change (6M)
—
Price change (YTD)
—
Price change (1Y)
—
Trailing year
Price change (5Y)
—
52-week high
$23.03
52-week low
$3.72
Change from 52-week high
-83.8%
Change from 52-week low
+0.0%
Annualized volatility
—
Annualized volatility (3M)
—
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
—
RSI (14D)
32.8
Price vs SMA 50
—
Price vs SMA 200
—
Avg volume (3M)
89,867
Relative volume
0.7
Average dollar volume
$640,259

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
1.80M

Valuation

12 metrics
P / E (TTM)
0.0
Trailing earnings · reciprocal yield 2,916.7%
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
1.9
reciprocal yield 53.2%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-70.9%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2021-06-30

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$16.34M
Net income (TTM)
−$4.76M
Trailing 12 months
Diluted EPS (TTM)
$108.50
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$5.67

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+1,300.6%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-133.4%
Return on assets
—
Debt / equity
—
Current ratio
2.6
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.96M
Latest balance sheet
Cash & equivalents
$4.96M
Total assets
$8.11M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$14.43M
Capital expenditures (TTM)
—
R&D (TTM)
$3.48M
SG&A (TTM)
$12.86M
Stock compensation (TTM)
$475,000
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
59
13F filer change QoQ
+17
Institutional ownership
4.7%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
0.7%
Private-fund adviser ownership
0.3%
Active holders' share change QoQ
+72.3%
Holder tenure
5.1
Price vs estimated holder cost
-86.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
1.3%

Short interest

3 metrics
Short interest
13.7%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
60 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 109657 CUSIP 36254L407 13F (30d) 26 filings 18 filers Visit website Investor relations